Given the potential for IFN responses to worsen hyper-inflammation, utilizing category I or III IFNs as a therapy for COVID-19 patients should be carefully considered, particularly for individuals with advanced disease phases [77]. This evidence concerns the gene IFNA1 and COVID-19.